| Name | SKL2001 |
| Description | SKL2001, an agonist of the Wnt/β-catenin pathway, can disrupt the Axin/β-catenin interaction. |
| Cell Research | The HEK293 reporter and control cell lines were established. The HEK293 reporter cells were inoculated into 384-well plates at 10 000 cells per well and grown for 24 h. Next, each compound in the chemical library (～270 000) was added to at a final concentration of 20 μM. After 15 h, the plates were assayed for firefly luciferase activity.(Only for Reference) |
| In vitro | SKL2001 upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3β enzyme activities. SKL2001 disrupted the Axin/β-catenin interaction, which is a critical step for CK1- and GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/β-catenin pathway. SKL2001 did not affect either NF-κB or p53 reporter activity and inhibits β-catenin phosphorylation without affecting GSK-3β activity[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (174.65 mM), Sonication is recommended.
Ethanol : 53 mg/mL (185.1 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | SKL2001 | Inhibitor | Wnt | Beta catenin | β-catenin | SKL-2001 | inhibit | SKL 2001 |
| Inhibitors Related | Urea | PRI-724 | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Neural Regeneration Compound Library | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Neuroprotective Compound Library | Anti-Fibrosis Compound Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |
United States
